• Tevogen Bio Holdings posted a net loss of USD 5.45 million for the quarter ended March 31, 2026, narrowing from a net loss of USD 10.37 million a year earlier.
• Operating loss improved to USD 5.4 million from USD 10.36 million, as total operating expenses fell to USD 5.4 million from USD 10.36 million.
• General and administrative costs dropped to USD 2.27 million from USD 7.16 million on lower legal and professional fees and stock-based compensation, while research and development spend edged down to USD 3.13 million from USD 3.2 million.
• Cash totaled USD 700,000 at March 31, 2026; the company cited funding visibility for at least 12 months, including USD 14 million available under its Loan Agreement and USD 7 million of additional committed grant funding from KRHP.
• Business updates included completion of a Phase 1 proof-of-concept trial of TVGN 489 in high-risk adult COVID-19 patients with no dose-limiting toxicities, and a May PIPE sale of prefunded common stock purchase warrants for about USD 3 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023920), on May 15, 2026, and is solely responsible for the information contained therein.